BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce highly promising results from a two-arm phase 1 clinical study of the safety and
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-08 8:00 AM EST | BioVaxys Technology Corp.
Broadreach Medical Resources (BMR) Announces Rebrand to HarmonyRx, Reflecting a New Era of Clinical-First Pharmacy Benefit Management
New York, New York--(Newsfile Corp. - January 7, 2026) - Broadreach Medical Resources (BMR), a leader in pharmacy benefit consulting and strategic clinical management, announces our rebrand to HarmonyRx-a name that represents the company's evolution, mission and commitment to aligning clinical excellence with financial value. The new brand identity reflects HarmonyRx's philosophy: that the most effective pharmacy strategies bring together evidence, clinical insight and cost stewardship
2026-01-07 8:08 AM EST | HarmonyRx
BioHarvest Sciences Issues Year End Shareholder Letter
British Columbia and Rehovot, Israel--(Newsfile Corp. - January 7, 2026) - BioHarvest Sciences Inc., (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or "the Company"), a company pioneering its patented Botanical Synthesis technology process, today issued a letter to shareholder partners from Chief Executive Officer, Ilan Sobel. Dear Fellow Shareholders, 2025 marked an important milestone for BioHarvest Scie
Biotechnology, Pharmaceuticals, Health
2026-01-07 7:30 AM EST | BioHarvest Sciences Inc.
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial shipment to the warehouse of Guri A.A.O. ("Guri"), a leading Israeli medical distribution company.
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-06 5:00 PM EST | TempraMed Technologies Ltd
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biopharmaceutical company focused on development of BETR-001, its proprietary non-hallucinogenic derivative of lysergic acid diethylamide ("LSD") for the treatment of neurological disorders, today announced that it will be participating in the YAFO Capital Access Asia 2025 Partnering Forum, held in San Franc
2026-01-06 8:00 AM EST | BetterLife Pharma Inc.
Telescope Innovations Outlines Global Market Opportunity for Self-Driving Labs and the Rising Adoption of Physical AI
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2026) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope" or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, is pleased to provide a strategic update regarding the accelerating commercial adoption of Self-Driving Labs (SDLs) and the global expansion of Physical AI. This update follows the Company's recent successful deployment of a
Technology, Chemical, Pharmaceuticals, Psychedelics
2026-01-05 8:00 AM EST | Telescope Innovations Corp.
CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition
Houston, Texas--(Newsfile Corp. - January 5, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced the launch of a national outreach and partnership initiative designed to capitalize on the accelerating federal momentum toward moving cannabis from Schedule I to Schedule III through the ongoing rescheduling rulemaking process. On December 18, 2025, a Presidential Exe
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-01-05 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead in 2026. As 2025 ends, the Company reflects on a transformative year marked by significant commercial progress, strategi
Technology, Biotechnology, Pharmaceuticals, Health
2026-01-02 5:00 PM EST | TempraMed Technologies Ltd
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that CEO Fabio Chianelli has published a letter to shareholders. Dear Shareholders, With 2025 complete, I want to thank you for your continued support of PharmaTher. This past year marked a shift from ambitious development to concrete validation, setting the stage for what I believe will be a value-unlocking year ahead
Biotechnology, Pharmaceuticals
2026-01-02 8:00 AM EST | PharmaTher Holdings Ltd.
TempraMed Deepens Asian Market Penetration with Expanded Distribution Partnership and Meaningful Commercial Order in South Korea
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce today a new commercial order and an extension of its distribution partnership in South Korea. The expanded collaboration with Mavericks Co. Ltd ("Mavens"), a South Korea–
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-31 5:00 PM EST | TempraMed Technologies Ltd
Hemostemix Closes $480,000 Private Placement at $0.12 per Share
Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, and vascular dementia, is pleased to announce that it has closed a non-brokered private placement for aggregate gross proceed
Biotechnology, Pharmaceuticals, Health
2025-12-31 2:38 PM EST | Hemostemix Inc.
Telescope Grants Stock Options, RSUs and Settles Debt with Shares
Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) (the "Company"), a leading developer of advanced technologies and services for the global pharmaceutical and high-value chemical industries announces that it has authorized the grant of incentive stock options (the "Options"), restricted share units (the "RSUs") as well as the issuance of common shares to settle outstanding fees owed to its
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-31 8:00 AM EST | Telescope Innovations Corp.
CBIH Announces New Patent Initiative Targeting Opioid Addiction Through Endocannabinoid Pathways
Houston, Texas--(Newsfile Corp. - December 29, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, today announced that it is pursuing a new patent for an investigational therapy designed to address opioid addiction, a condition that continues to claim tens of thousands of lives each year in the United States. According to U.S. public health data, more than 700,000 people have died
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-29 7:00 AM EST | Cannabis Bioscience International Holdings
TempraMed Launches New Product, VIVI Cap Smart, Expanding Its Portfolio to Include a Digital Health Offering
Highlights: Expands TempraMed's product portfolio and adds a digital component to track and record medication use. First in the world platform that turns almost every insulin and GLP-1 pens to be connected and with a temperature shield. Unlocks significant pharma, healthcare provider, and real-time data opportunity to track compliance, efficacy, side effects, and other important information. Adds subscription-based business model to produ
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-26 5:00 PM EST | TempraMed Technologies Ltd
Telescope Innovations Reports Significant Milestones and Financial Results of Fiscal Year 2025
Vancouver, British Columbia--(Newsfile Corp. - December 23, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a developer of intelligent automation and advanced chemical manufacturing technologies, reports financial results for the fiscal year ended August 31, 2025. The Company generated revenues of $5.8 million during this period, with an Adjusted EBITDA loss of $402K (Figure 1). Telescope continues
Technology, Chemical, Pharmaceuticals, Psychedelics
2025-12-23 8:00 PM EST | Telescope Innovations Corp.
Theralase(R) Closes $1.3 M Non-Brokered Private Placement
Toronto, Ontario--(Newsfile Corp. - December 23, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses is pleased to announce that it has successfully closed a non-brokered private placement offering ("Offering") of units ("Units"). On
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-23 4:40 PM EST | Theralase Technologies Inc.
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, total body ischemia, vascular dementia, is pleased to announce the appointment of Dr. David B. Alper, DPM, FFPM RCPS, to a lead role as Multidisciplinary Physic
Biotechnology, Pharmaceuticals, Health
2025-12-23 9:10 AM EST | Hemostemix Inc.
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it has taken a
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-23 8:45 AM EST | Phio Pharmaceuticals Corp.
CBIH Welcomes Federal Momentum Toward Cannabis Rescheduling as 2026 Opens a New Window to Accelerate Medical Innovation and Growth, with CBIH Positioned to Capitalize on Emerging Opportunities
Houston, Texas--(Newsfile Corp. - December 22, 2025) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH) (CBIH) announces a landmark corporate and industry moment following recent indications that President Donald Trump will support federal actions that advance the rescheduling of marijuana from Schedule I to Schedule III. The development is widely regarded as one of the most consequential policy shifts in nearly two decades of national debate. After eighte
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-22 7:00 AM EST | Cannabis Bioscience International Holdings
Herbal Dispatch CEO Philip Campbell Weighs in on Global Implications of USA Cannabis Reclassification to Schedule III
Vancouver, British Columbia--(Newsfile Corp. - December 19, 2025) - Herbal Dispatch Inc. (CSE: HERB) (OTC Pink: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company") a leading Canadian cannabis e-commerce platform specializing in small-batch craft cannabis, today shared insights from CEO Philip Campbell regarding President Trump's landmark decision to shift cannabis from Schedule I to Schedule III under the U.S. Controlled Substances Act. "This development stands a
Pharmaceuticals, Cannabis, Cannabis Dispensary
2025-12-19 9:51 AM EST | Herbal Dispatch Inc.